Gene therapy trial aims to halt blindness in dry AMD

NCT ID NCT06018558

Ongoing Disease control Sponsor: Ocugen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a gene therapy called OCU410 for geographic atrophy, a severe form of dry age-related macular degeneration that causes vision loss. About 60 adults aged 50 and older will receive a single injection of OCU410 into the eye. Researchers will monitor safety and check if the treatment can preserve or improve vision over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OCU410 (gene therapy)
What this could lead to: If successful, this could lead to a treatment that slows or stops vision loss from geographic atrophy in dry age-related macular degeneration.
What could go wrong: This is an early phase 1/2 trial with only 60 participants, so results may not confirm effectiveness or safety. Gene therapy carries risks like inflammation or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry age related macular degeneration Geographic Atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GEOGRAPHIC ATROPHY

Contacts and locations

Show contact details

Locations

A) Retina Foundation of the Southwest

Dallas, Texas, 75231, United States
Advanced Research, LLC

Coral Springs, Florida, 33067, United States
Associated Retina Consultants

Phoenix, Arizona, 85020, United States
B) Retina Consultants of Texas

Bellaire, Texas, 77401, United States
Duke Eye Center

Durham, North Carolina, 27710, United States
Gundersen Health System

La Crosse, Wisconsin, 54601, United States
Mid Atlantic Retina

Cherry Hill, New Jersey, 08034, United States
Miidwest Eye Institute

Carmel, Indiana, 46290, United States
Mississippi Retina Associates

Jackson, Mississippi, 39202, United States
The Retina Institute

St Louis, Missouri, 63128, United States
The University of Pittsburgh

Pittsburgh, Pennsylvania, 15260, United States
Valley retina Institute

McAllen, Texas, 78503, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.